News | July 15, 2022
Evonik now offers enteric protected ready to fill capsules EUDRACAP in IPEC-GMP quality
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Plant is part of the company's CAD $30 million capital investment in the site
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Subscribe To Our Newsletter & Stay Updated
